Perspectives on dietary polyunsaturated fatty acid supplementation for enhanced immunity in healthy and ill dogs: a narrative review Authors: Carolina Barroso, António JM Fonseca, Ana RJ Cabrita Published: 2026 ABSTRACT Highlights•Fish oil-rich diets decrease the production of pro-inflammatory eicosanoids.•EPA and DHA decrease inflammatory cytokines in dogs with cardiac pathologies.•Novel n-3 sources including microalgae, krill and fish by-products remain poorly used.•Current research remains insufficient to establish an optimal n-6 to n-3 ratio.•Elucidating immune mechanisms will allow the development of evidence-based canine diets.Keywords: Dogs, Functional foods, Immune responses, Inflammation, Polyunsaturated fatty acids Introduction The number of dogs in Europe increased from approximately 90 million in 2023 to over 91 million in 2024 (FEDIAF, 2025a; 2026). The relationship between humans and dogs has fueled the humanization of pets, with animals being considered as family members with human-like needs and emotions (Boya et al., 2012; Prato-Previde et al., 2022). This is evidenced by the increasing interest in diets that not only provide essential nutrients but that also include functional ingredients or supplements that promote dogs’ health and well-being (Baritugo et al., 2023; Barroso et al., 2024). Thus, the pet food sector is currently experiencing a significant development to offer foods with functional properties tailored to dogs’ needs, health conditions and life stage. It is recognized that polyunsaturated fatty acids (PUFAs), namely omega-3 (n-3) and omega-6 (n-6), are essential components in dogs’ diets, playing important roles in the maintenance of skin and coat health, brain development, and visual acuity (Heinemann et al., 2005; Rees et al., 2001; Zicker et al., 2012). Dogs cannot synthesize alpha-linolenic acid (ALA; 18:3n-3) and linoleic acid (LA, 18:2n-6) endogenously due to the absence of desaturase enzymes (∆-12 and ∆-15) required for the insertion of double bonds at particular positions of the fatty acid structure. Therefore, these PUFAs are essential nutrients that must be included in the diet, with the National Research Council (NRC, 2006) and the European Pet Food Industry Federation (FEDIAF, 2025b) setting minimum requirements for dogs at all life stages. Furthermore, since canines present a limited capacity to convert ALA to the long-chain (LC) PUFAs eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3; Bauer et al., 1998), these two fatty acids must also be provided through the diet. The main dietary sources of ALA and LA include vegetable oils such as linseed, canola, corn or safflower, while fish oils are the primary sources of EPA and DHA in dog foods (Burron et al., 2024). Both n-6 and n-3 are involved in inflammatory responses (Calder, 2020; Innes & Calder, 2018; Serhan & Petasis, 2011). In particular, EPA and arachidonic acid (ARA; 20:4n-6) serve as precursors to a range of bioactive lipid mediators, including prostaglandins and leukotrienes (Calder, 2020). Furthermore, n-3 modulate T-cell proliferation, inhibits the expression of pro-inflammatory cytokines and serve as precursors of pro-resolving mediators, limiting the inflammatory response (Serhan & Petasis, 2011; Wu et al., 2019). Studies in humans have shown potential benefits of n-3 in chronic inflammatory conditions such as systemic lupus erythematosus or rheumatoid arthritis (Hong et al., 2024; Miles & Calder, 2012). In dogs, despite dietary supplementation with n-3 has been shown to be beneficial in managing osteoarthritis, dermatological and cardiac diseases (Barbeau-Grégoire et al., 2022; van Amersfort et al., 2023; Vendramini et al., 2025), its anti-inflammatory effects remain poorly understood. Indeed, despite the growing number of commercial pet foods and supplements claiming anti-inflammatory and immune-enhancing properties of PUFAs, published studies regarding their effects on the immune responses of dogs remain significantly limited when compared to studies using other animal models. Moreover, to the authors' knowledge, no comprehensive review has been dedicated exclusively to the immunomodulatory effects of dietary PUFAs in dogs, as the existing literature has largely focused on different clinical conditions. Considering the recognized role of PUFAs in immune modulation and the limited evidence regarding their effects on inflammatory and immune responses in dogs, a critical evaluation of the available literature is warranted. As such, this review summarizes the current knowledge on the effects of dietary PUFAs – particularly LA, ALA, EPA and DHA – on canine immunity, focusing on three main objectives: (1) synthesizing the available evidence on the immunomodulatory effects of dietary PUFAs in dogs, both in healthy animals and in those with different natural or experimentally induced pathologies; (2) evaluating emerging sustainable PUFA sources, including microalgae, insect and krill oils, and their potential application in functional canine diets; and (3) identifying key methodological limitations and knowledge gaps to guide future research. The present review is particularly timely given the rapid expansion of the functional pet food market and the emergence of novel sustainable n-3 sources, whose immunomodulatory potential in dogs remains largely unexplored. By addressing these objectives, this review aims to support the development of evidence-based canine diets incorporating functional PUFAs, thereby improving immune function and canine health. Methods Literature search Two electronic databases (PubMed and Web of Science) were searched for articles published in English between January 1990 to December 2024, using the following terms in the title and abstract: (Canine OR Dogs OR Dog) AND (Polyunsaturated Fatty Acids OR PUFA OR Omega OR n-3 OR n-6 OR Eicosapentaenoic acid OR EPA OR Docosahexaenoic acid OR DHA OR Alpha-linolenic acid OR ALA OR Linoleic acid OR LA) AND (Immune modulation OR Immunological OR Immune OR Immune function OR Immune response OR Inflammatory OR Immunity OR Cytokines OR Immune system OR Immunoglobulins OR Immune cells OR Phagocytic activity OR Pro-inflammatory OR Anti-inflammatory OR Innate immunity OR Acquired immunity OR Lymphocyte OR Monocyte OR Macrophage OR Neutrophil OR Granulocyte OR Immunology). All articles (n = 1195) were retrieved from the databases in December 2024, inserted into an EndNote library (EndNoteTM 21.2, Clarivate, Philadelphia, PA, USA), and all duplicates were then removed (n = 496). The resultant list of studies (n = 699) was then screened according to the exclusion and inclusion criteria described below and 25 articles were selected. To ensure a complete analysis of the available literature, an additional search was performed using the reference list of relevant articles (e. g. reviews or original articles focused on PUFA supplementation). Citation alerts of previously published works by the authors were also screened for inclusion. Through this search, additional studies (n = 5) that met the criteria for inclusion were identified. To guarantee that articles published during the preparation of the manuscript were included, a new search was conducted in October 2025, resulting in the identification of two additional articles, thus a total of 32 articles were included in the final list. The complete selection process is shown in Figure 1. Flow diagram for the literature review. Reviews also include book chapters, editorials or opinion articles. The criteria “immune responses not analyzed” also include the ones that only measured blood parameters and/or CRP. Exclusion criteria Studies obtained from databases were first excluded if: 1) were review articles, book chapters, or editorials; 2) were conference abstracts; 3) the full text was not available; 4) did not use dogs as the animal model; 5) were conducted in vitro or ex vivo; and 6) were case reports or retrospective studies. The remaining articles were then screened and were excluded if: 1) did not evaluate the effects of a dietary intervention; 2) did not involve a dietary intervention based on PUFAs; 3) immune or inflammatory outcomes were not evaluated; or 4) only reported blood counts, serum biochemistry and/or inflammatory biomarkers (e.g., C-reactive protein, CRP), without an assessment of other immune responses, such as cytokines, eicosanoids, or other direct immunological parameters. Inclusion criteria Studies were included if they assessed the in vivo effects of dietary supplementation with PUFAs on immune or inflammatory responses in dogs. Eligible results included: 1) eicosanoids or cytokines; 2) cellular or tissular expression of immune-related genes; 3) immune cell phenotyping; 4) cellular responses (e.g., chemotaxis, phagocytosis, lymphocyte proliferation); 5) tissue inflammatory cell infiltration; 6) antibody responses; or 7) delayed-type hypersensitivity (DTH) responses. The included articles were subsequently grouped into studies involving healthy dogs and those involving dogs with natural or experimentally induced pathologies. For each included study, the following data were extracted: number and characteristics of animals (breed, age, and health status), study design, type and dose of PUFA supplementation, duration of intervention, and immune and inflammatory outcomes assessed. The extracted information was summarized in tabular format to enable comparison among studies. This review aimed to provide a narrative synthesis of the available evidence regarding the effects of dietary PUFA supplementation on immune and inflammatory responses in dogs. The substantial heterogeneity among the studies, including differences in study design, canine populations, PUFA sources and supplementation protocols, and immune outcomes assessed precludes a meta-analysis and justifies the use of a narrative synthesis. The available evidence was critically evaluated and discussed according to the health status of dogs, type and source of PUFA supplementation, and the main findings of each study. This approach facilitated the identification of major patterns within the literature and highlighted current knowledge gaps requiring further investigation. Limitations of the review process Several limitations of the present review should be acknowledged. The literature search was restricted to two electronic databases (PubMed and Web of Science), to articles published in English and between January 1990 and December 2024, which may have resulted in the omission of relevant studies indexed in other databases (e.g., Scopus, Google Scholar) or published in other languages. Second, as this is a narrative review, no risk of bias assessment or quality of individual studies was performed. As such, methodological differences among studies, including variations in sample size, study design, duration of intervention, PUFA source and composition, may contribute to differences in reported findings and should be taken into account when interpreting the evidence summarized in this review. Third, the review was not registered in a database such as PROSPERO, which limits the verifiability of the protocol. Despite these limitations, the structured search strategy, the use of manual searching of reference lists, and the update search conducted in October 2025 aimed to ensure a comprehensive and up-to-date overview of the available evidence. Metabolism of PUFAs in dogs Both ALA and LA serve as substrates for the same enzymes, and thus, a competitive relationship exists between these fatty acids. Enzyme ∆-6 desaturase is crucial for the initial desaturation of ALA and LA, being the following elongation and desaturation mediated by ∆-5 desaturase (NRC, 2006). As dogs are able to synthesize ARA from LA, requirements for the former can be met with an adequate supply of dietary LA (Fig. 2; Burron et al., 2024; Lenox, 2015; NRC, 2006). Alpha-linoleic acid can be converted to EPA through the same enzymes; however, to produce DHA, additional elongation and desaturation steps promoted by elongase and Δ-6 desaturase are needed, followed by a final β-oxidation step in peroxisomes (Fig. 2; NRC, 2006). Modest increases in plasmatic EPA levels were observed in dogs fed an ALA-enriched diet, suggesting that while dogs can synthesize EPA from ALA, the conversion rate is inefficient (Bauer et al., 1998). The synthesis of DHA is even more limited, as dogs showed no significant alterations in DHA levels in plasma, despite the increases observed in plasmatic docosapentaenoic acid (DPA, 22:5n-3), an intermediate fatty acid between EPA and DHA synthesis (Bauer et al., 1998). Pathways of long-chain n-3 and n-6 PUFA synthesis. Polyunsaturated fatty acid requirements for dogs The NRC is a government-funded agency from the USA that evaluates research performed by external institutions and industries to establish minimum nutrient recommendations across different life stages, namely growth, reproduction, and adult maintenance (NRC, 2006). The FEDIAF serves as the trade body representing the European pet food industry and has developed nutritional guidelines for dogs by conducting an extensive review of NRC data alongside other existing scientific literature as a practical guide for researchers and manufacturers (FEDIAF, 2025b). Pet food products in Europe can only be labeled as “complete and balanced” if they meet or exceed the nutritional guidelines established by FEDIAF (2025b). Both NRC (2006) and FEDIAF (2025b) establish minimum recommended levels of PUFAs for dogs, with variations depending on life stage (Table 1). Although FEDIAF requires pet food companies to meet their minimum guidelines for fatty acid provision, there is no requirement to list quantities of fatty acids on the labeled nutrient profile of the diet. Minimum levels of LA for growth, reproduction and adult dogs at maintenance are recommended by both NRC and FEDIAF, whereas for ALA and EPA + DHA, FEDIAF (2025b) limits its recommendations to puppies and reproduction. Regarding the minimum requirements for ARA, NRC (2006) has set minimum levels for puppies, while FEDIAF extends its minimum recommended levels to both puppies and reproductive females. Table 1Recommended allowances (NRC, 2006) and minimum levels (FEDIAF, 2025b) of polyunsaturated fatty acids for dogs1.Table 1 dummy alt textNRCAdultGrowthLate Gestation and Peak LactationLA11.0013.0013.00ALA0.440.800.80ARA-0.30-EPA + DHA0.440.500.50FEDIAFAdult2Growth/ Reproduction95 kcal/kg0.75110 kcal/kg0.75LA15.3013.2013.00ALA--0.80ARA--0.30EPA + DHA--0.501Values expressed as g/kg of dry matter (DM) and assuming 4000 kcal of metabolizable energy/kg DM.2Recommended values based on maintenance energy requirement of 95 kcal/kg0.75 and 110 kcal/kg0.75.ALA: Alpha-linolenic acid; ARA: Arachidonic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; LA: Linoleic acid. Recommended allowances (NRC, 2006) and minimum levels (FEDIAF, 2025b) of polyunsaturated fatty acids for dogs1. Values expressed as g/kg of dry matter (DM) and assuming 4000 kcal of metabolizable energy/kg DM. Recommended values based on maintenance energy requirement of 95 kcal/kg0.75 and 110 kcal/kg0.75. ALA: Alpha-linolenic acid; ARA: Arachidonic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; LA: Linoleic acid. A deficiency in essential fatty acids leads to skin and coat issues, including matted coat, scaly skin, increased transepidermal water loss (TEWL), and impaired wound healing capacity (Kirby et al., 2007), as well as impacts canine growth, reproduction, and visual and neural functions (Bauer, 2016; Heinemann & Bauer, 2006; NRC, 2006). Beyond the dietary level of essential fatty acids, the balance between n-3 and n-6 PUFAs is crucial for maintaining physiological functions. However, the ideal ratio of n-6:n-3 for dogs has not yet been defined, with the NRC (2006) suggesting a n-6:n-3 ratio between 2.6:1 and 26:1, while FEDIAF (2025b) acknowledges that the current data on n-3 supplementation is insufficient to recommend specific levels of these fatty acids to adult dogs. Nevertheless, according to a recent review discussing the significance of n-6 and n-3 fatty acids in companion animals, current evidence suggests that a ratio below 10:1 should be targeted for dogs (Burron et al., 2024). Sources of PUFAs in canine foods Traditional sources Several vegetable and animal oils and fats can be included in canine foods to offer adequate amounts of PUFAs (Table 2). The content of LA is particularly high in some vegetable oils, including corn, cottonseed, safflower, sunflower, sesame, soybean and hemp, while linseed oil contains the highest content of ALA. Camelina, canola, soybean, linseed and hemp contain high levels of both LA and ALA, thereby a more balanced n-6:n-3 ratio. Olive and palm oils are also used in canine diets, but contain lower amounts of LA and ALA. Likewise, animal fats such as white grease, lard or poultry fat can also supply some amounts of LA, yet their content of ALA is also considerably low. Table 2Contents of polyunsaturated fatty acids in different oil and fat sources.Table 2 dummy alt text% of total fatty acidsLA(18:2n-6)ALA (18:3n-3)ARA(20:4n-6)EPA (20:5n-3)DHA (22:6n-3)ReferenceVegetable oilsCamelina19.835.4---Burron et al. (2021)Canola20.39.3---NRC (2006)Corn59.00.7---NRC (2006)Cottonseed51.50.2---NRC (2006)Hemp58.716.8---Xin et al. (2022)Linseed12.753.3---NRC (2006)Olive7.90.6---NRC (2006)Palm9.10.2---NRC (2006)Safflower74.10.4---NRC (2006)Sesame41.30.3---NRC (2006)Soybean51.06.8---NRC (2006)Sunflower39.80.2---NRC (2006)Animal fatsBeef tallow3.10.6---NRC (2006)Lard10.21.0---NRC (2006)Poultry fat19.51.0---NRC (2006)White grease11.60.4---NRC (2006)Fish oilsAnchovy1.20.80.117.08.8NRC (2006)Cod liver1.40.61.611.212.6NRC (2006)Herring1.10.60.38.44.9NRC (2006)Menhaden1.30.30.211.09.1NRC (2006)Salmon (sea caught)1.20.60.912.013.8NRC (2006)MicroalgaeSchizochytrium sp.20.520.060.050.0917.63Zhu et al. (2022)Chlorella vulgaris18.4132.570.280.19BDL1Cabrita et al. (2022)Nannochloropsis oceanica3.450.285.7222.14BDL1Cabrita et al. (2022)Tetradesmus obliquus6.7634.070.160.310.36Cabrita et al. (2022)InsectsBlack soldier fly (Hermetia illucens) larvae12.53.40.11.70.7Ewald et al. (2020)Mealworm (Tenebrio molitor) larvae29.81.08-0.020.07Jajic et al. (2020)Marine sourcesKrill oil2.00.20.318.67.8Fuller et al. (2020)1Fatty acid composition of microalgae powder.2BDL: Below the detection limits.ALA: Alpha-linolenic acid; ARA: Arachidonic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; LA: Linoleic acid. Contents of polyunsaturated fatty acids in different oil and fat sources. Fatty acid composition of microalgae powder. BDL: Below the detection limits. ALA: Alpha-linolenic acid; ARA: Arachidonic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; LA: Linoleic acid. Eicosapentaenoic acid and DHA are primarily obtained from marine organisms, particularly fatty fish (e.g., anchovies, menhaden, or salmon), with anchovies containing the highest proportion of EPA and salmon the highest content of DHA. Fish oil has been the primary source of EPA and DHA in both human and animal nutrition. While plant-derived oils represent valuable sources of short-chain n-3 PUFAs, the limited conversion into EPA and DHA have led to the continued dependency on marine-derived ingredients. However, growing concerns regarding the sustainability of marine resources, including overfishing, the presence of chemicals, and fluctuations in fish stocks, have fueled the search for alternative LC PUFA sources (Jacobs et al., 2004; Liu & Dave, 2022; Swetha & Mathanghi, 2024). Consequently, novel sources of n-3 PUFAs have emerged, including microalgae, krill, and marine by-products, which are increasingly recognized as promising alternatives that can reduce pressure on wild fish stocks and support circular economy approaches (Adarme-Vega et al., 2012; 2014; Cooney et al., 2023). This shift from conventional fish oil towards more sustainable PUFA sources reflects the growing environmental, economic, and regulatory concerns, and is expected to represent a key future direction in human and animal nutrition (Cabrita et al., 2024a, Cooney et al., 2023). Emerging sustainable sources Among the emerging sustainable alternatives, microalgae are gaining particular attention due to their higher efficiency of production when compared to terrestrial plants, ease of cultivation, and their role as primary producers of EPA and DHA at the base of the marine food chain, making them promising and sustainable alternatives to fish oil (Deepika et al., 2026; Zakaria et al., 2025). Depending on the species and cultivation conditions, microalgae can be considered good sources of DHA (Schizochytrium sp.; Zhu et al., 2022), ALA and LA (Chlorella vulgaris), ALA (Tetradesmus obliquus), EPA and ARA (Nannochloropsis oceanica; Cabrita et al., 2022). Despite their nutritional potential, the application of microalgae in pet foods remains largely unexplored. Schizochytrium sp. has been tested as a DHA source, with supplementation associated with improvements in coat quality and antioxidant capacity, as well as with support of a healthy brain function during senescence (Hadley et al., 2017; Zhang et al., 2025). In another study, the inclusion of N. oceanica at 1.5% on top of the reference diet substantially increased dietary EPA content (from 0.028 to 0.295 g/kg of dry matter, DM), highlighting its potential as a sustainable source of LC n-3 PUFAs for canine foods (Cabrita et al., 2023). Krill, small shrimp-like crustaceans that consume algae, constitute another sustainable source of EPA and DHA (Köhler et al., 2015). According to recent research, the introduction of krill oil and meal in dog foods increased the omega-3 index (O3I), compared to flaxseed and even to fish oil (Burri et al., 2018; Dominguez et al., 2021; Lindqvist et al., 2023), and was linked to a decrease in the exercise-induced rise in serum CRP levels (Burri et al., 2018). The O3I measures the levels of EPA and DHA in red blood cell membranes, serving as a biomarker for long-term n-3 intake. In humans, this index is negatively correlated with the neutrophil-lymphocyte ratio, a marker of systemic inflammation (McBurney et al., 2022; Walker et al., 2019). In dogs, the introduction of the O3I as a biomarker represents an important methodological advancement with potential clinical relevance. Its application may support future studies aimed at establishing reference ranges and determining its value as a biomarker across a range of physiological and pathological conditions (Harris et al., 2023). A recent study reported that the dietary supplementation with 70 mg of EPA + DHA/kg/day from fish oil increased the O3I and was accompanied by an improvement in pain and quality of life scores in dogs, although no significant correlation was found between the two outcomes. An O3I value above 3% was proposed as a potential threshold for improved health outcomes in future studies (Carlisle et al., 2024). The processing of fish for consumption generates substantial amounts of by-products, including heads, frames, trimmings, viscera, skin, and scales, which account for over 50% of the fish’s body, creating opportunities for the use of these by-products as n-3 sources (Liu & Dave, 2022; Rodrigues et al., 2024). Recently, the dietary inclusion of protein hydrolysate and oil derived from fish waste was shown to increase the O3I in adult dogs, thus suggesting health-promoting effects, and aligning with circular economy principles (Cabrita et al., 2024a; 2024b). These results might be attributable to the higher content of EPA and DHA (1.25 and 1.96 g/100g of total fatty acids, respectively) of the experimental diet when compared to the control diet with shrimp hydrolysate and salmon oil (0.355 and 0.494 g/100g of total fatty acids of EPA and DHA, respectively). Insects, such as black soldier fly (BSF; Hermetia illucens) and mealworm (Tenebrio molitor), are also recognized as novel and sustainable sources to be used in pet food (Valdés et al., 2022), presenting high amounts of LA and reasonable amounts of ALA, but their content in LC PUFAs is usually low. Yet, these concentrations may vary depending on the species and rearing conditions (Ewald et al., 2020; Jajic et al., 2020; Rabani et al., 2019). To the best of authors knowledge, the use of insects as sources of PUFAs in dogs is scarcely investigated. In a recent study, dogs fed a diet containing BSF larvae (BSFL) meal showed improvements in skin barrier functions (as measured by TEWL and stratum corneum hydration), that could be related to the higher content of LA and lauric acid (1.62 and 1.56 g/100g as is, respectively) when compared to the control diet containing poultry by-product (1.31 and <0.10 g/100g; Silva Carvalho et al., 2024). Stability of PUFAs in canine foods Mechanisms of lipid oxidation Oils rich in LC PUFAs are highly susceptible to oxidation due to the presence of multiple double bonds. Lipid oxidation is influenced by several external factors, including temperature, light, and oxygen exposure, resulting in the formation of compounds that reduce the nutritional quality, functional properties, and palatability of foods (Domínguez et al., 2019; Wang et al., 2021). Lipid oxidation occurs mainly through autoxidation, enzymatic oxidation and photosensitized oxidation (Wang et al., 2021). These processes generate primary oxidation products (lipid hydroperoxides), which subsequently decompose into secondary compounds, such as aldehydes (e.g., malondialdehyde [MDA] and 4-hydroxynonenal), responsible for the characteristic off-flavors of oxidized foods and potentially detrimental biological effects (Rodrigues et al., 2024; Shahidi & Hossain, 2022, Zhao et al., 2025). In dogs, dietary oxidized lipids have been associated with reduced growth, lower serum vitamin E concentrations, impaired neutrophil and monocyte oxidative burst, decreased lymphocyte proliferation, and increased bone loss in puppies (Turek et al., 2003). Assessment of lipid peroxidation Lipid peroxidation is commonly assessed by measuring primary and secondary oxidation products. Peroxide value quantifies hydroperoxides formed in the primary stages of oxidation (Zhang et al., 2021). Secondary oxidation products are most frequently evaluated by measuring MDA, typically using the thiobarbituric acid reactive substances (TBARS) assay (Abeyrathne et al., 2021; Tsikas, 2017). Although TBARS remains the most widely used method because of its simplicity, chromatographic techniques (e.g., GC-MS and HPLC) provide greater specificity and sensitivity for assessing lipid oxidation (Abeyrathne et al., 2021; Niki, 2014; Papastergiadis et al., 2012). Stability challenges in pet foods Manufacturing commercial foods poses significant challenges in maintaining the stability of PUFAs. Extrusion conditions, such as screw, speed and temperature, as well as water content, can significantly affect the oxidative stability of foods (Hülsebusch et al., 2025). High extrusion temperatures (200 °C) were found to decrease the content of ALA and LA in a canine diet extruded using a 4 mm die, while no major decreases were observed in EPA and DHA (Tran et al., 2011). High temperatures applied during extrusion can also increase the concentration of pro-oxidant transition metals, or decrease antioxidant content (Brennan et al., 2011; Lin et al., 1998; Singh et al., 2007). Temperature and period of storage can also significantly impact the oxidative stability of lipids in dry dog foods (Hołda & Głogowski, 2016). Additives are commonly included in pet foods to increase stability, maintain the organoleptic properties, and the nutritional and functional values. Synthetic antioxidants, particularly butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT), are commonly used in pet foods with a maximum level of 150 mg/kg as established by the European Food Safety Authority (EFSA, 2018). While effective in preventing oxidation of lipids, they are associated with several health issues, including carcinogenicity, cytotoxicity or endocrine disrupting effects (Xu et al., 2021). As such, natural antioxidants, encapsulation, and nanotechnology-based delivery systems are increasingly recognized as important strategies for preserving PUFA stability and bioactivity in foods, thereby helping to maintain their nutritional and functional properties (Hrebień-Filisińska, 2021; McClements & Öztürk, 2021; Zhong et al., 2025). Natural and emerging strategies for PUFA stabilization Natural antioxidants include vitamin C (ascorbic acid), vitamin E (tocopherols), carotenoids, and polyphenols, which mainly exert their activity by scavenging free radicals, chelating transition metals and reacting with single oxygen atom (Gülçin, 2010; Miazek et al., 2022). Beyond protecting fatty acids from oxidative degradation, these compounds also exert health promoting effects in dogs. Indeed, a recent review highlighted that vitamins, carotenoids, and polyphenols can present immunomodulatory properties and reduce inflammation associated with several pathologies, such as obesity, inflammatory bowel disease and osteoarthritis (Barroso et al., 2024). Vitamins E and C, β-carotene and rosemary extracts have been recently studied as natural antioxidants in extruded dry pet foods, with improved antioxidant activity, enhanced cell protection and reduced DNA damage (Jewell et al., 2024; Ren et al., 2024). Moreover, natural antioxidants (cranberry, curcumin, grape seed extract and pomegranate) were shown to exert a higher decrease of lipid peroxidation in dog food after 12 days of storage, and improved the stability of EPA and DHA, when compared with BHA (Glodde et al., 2018). Schlieck et al. (2021) tested a blend of essential oils from clove, rosemary, oregano, and vitamin E as natural antioxidants for dog foods, comparing with BHT. Diet containing the blend did not show differences from the control diet regarding TBARS, reactive oxygen species (ROS), protein thiols and non-protein thiols for 12 months, demonstrating the potential of natural antioxidants in preventing lipid peroxidation in foods. Beagle dogs fed both diets during periods of 28 days showed increased glutathione S-transferase and non-protein thiol levels and lower ROS, showing that the blend stimulated the antioxidant function. Nanotechnology has emerged as a potential strategy for encapsulating, protecting, and delivering several bioactive compounds in food products, using various delivery systems such as nanoemulsions, solid lipid nanoparticles, nanoliposomes, or nanoparticle-stabilized pickering emulsions (McClements & Öztürk, 2021). These delivery systems have been studied for the encapsulation of n-3 to improve stability, bioavailability and potential therapeutic properties for humans, particularly in the context of cardiovascular, inflammatory and cancer diseases (Gill et al., 2024; Serini et al., 2019; Yaghmur et al., 2023). The application of nanotechnology in animal nutrition and veterinary medicine has also gained increasing attention, with evidence supporting its potential to improve nutrient bioavailability, animal performance, and disease management (Almeida et al., 2024; Kazemi, 2025). In this context, a study conducted in Nile Tilapia (Oreochromis niloticus) fed diets with nanoencapsulated EPA and DHA showed improvements in animal growth performance, immunity, and resistance against Aeromonas hydrophila (Ibrahim et al., 2022). However, to the best of the authors' knowledge, no studies have yet addressed the inclusion of such delivery systems to protect and deliver PUFAs in canine diets. Given the susceptibility of PUFAs to oxidative degradation during processing and storage, and the growing evidence supporting the immunomodulatory potential of these fatty acids in dogs, nanotechnology-based formulations represent a promising and underexplored research line that warrants further investigation. Immunomodulatory mechanisms of PUFAs It is established that PUFAs influence inflammatory and immune responses, although most mechanistic evidence has been generated from studies in humans and rodent models (Fritsche, 2015; Serhan & Petasis, 2011; Wu et al., 2019). Cells involved in inflammation are typically enriched in ARA, but the content of PUFA in cell membranes can be modified through dietary supplementation with EPA and DHA. These changes alter membrane biophysical properties and the organization of lipid rafts, which serve as platforms for receptor clustering and intracellular signaling. For example, incorporation of n-3 PUFAs into CD4+ T-cell membranes alters lipid raft organization, thereby modulating receptor signaling, cell activation, and proliferation (Fan et al., 2018; Kim et al., 2008). Likewise, preclinical studies have also shown that n-3 PUFAs can influence B-cell antigen presentation, cytokine production, and antibody responses, potentially through changes in B-cell lipid rafts and T-helper 2-associated cytokine signaling (Whelan et al., 2016; Wu et al., 2019). Moreover, PUFAs regulates signal transduction pathways, influencing transcription factor activity, gene expression, and the availability of substrates for the synthesis of different lipid mediators (Calder, 2011, 2020). The expression of several pro-inflammatory genes is regulated by the transcription factor nuclear factor kappa B (NF-κB). Eicosapentaenoic acid inhibits lipopolysaccharide (LPS)-induced NF-κB activation in human monocytic cells, reducing the production of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α; Zhao et al., 2004). Long-chain n-3 PUFAs also activate peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor that further suppresses NF-κB-dependent gene expression (Li et al., 2005). Similarly, ALA inhibits NF-κB signaling in LPS-stimulated RAW264.7 macrophages following activation of the G protein-coupled receptor 120 (Liu et al., 2022). Following inflammatory stimulation, phospholipase A₂ releases ARA from membrane phospholipids, providing substrate for cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 enzymes to generate a variety of bioactive lipid mediators, including prostaglandins, leukotrienes and thromboxanes (Innes & Calder, 2018). Prostaglandin E2 (PGE₂) promotes fever, vascular permeability, and interleukin (IL)-6 production, although its effects on T-cell responses are context dependent (Innes & Calder, 2018; Sreeramkumar et al., 2012). Leukotriene B4 (LTB4) is a potent chemoattractant that promotes immune cell recruitment, cytokine production, antimicrobial defense, and lymphocyte trafficking (Di Gennaro & Haeggström, 2014). Thromboxane A₂ (TXA₂) contributes to platelet aggregation, vasoconstriction, and inflammatory vascular responses (Darwesh et al., 2019). Eicosapentaenoic acid competes with ARA for these enzymatic pathways, giving rise to alternative lipid mediators such as PGE3, LTB5, and TxA3, which generally exhibit lower pro-inflammatory activity than their ARA-derived counterparts (Calder, 2011, 2020). For example, PGE3 promotes M2a macrophage polarization (Cui et al., 2021), LTB5 is a weaker leukocyte chemoattractant than LTB4 (Calder, 2020), and TxA3 has reduced platelet aggregating activity compared with TxA2 (Darwesh et al., 2019). During inflammation, prostaglandins and leukotrienes contribute to the initiation and amplification of the inflammatory response. As inflammation progresses, a lipid mediator class switching leads to the generation of specialized pro-resolving mediators (SPMs) from EPA and DHA, including resolvins and protectins. Rather than simply suppressing inflammation, these mediators actively coordinate its resolution by limiting neutrophil infiltration, promoting macrophage-mediated clearance of apoptotic cells and cellular debris, and reducing the production of pro-inflammatory cytokines such as IL-1β and TNF-α (Serhan et al., 2008; Serhan & Levy, 2018; Serhan & Petasis, 2011). Arachidonic acid also contributes to the resolution phase through the production of lipoxins, highlighting that its immunological effects are context-dependent rather than exclusively pro-inflammatory (Serhan, 2014). Collectively, these mechanisms demonstrate that PUFAs regulate immune responses through coordinated effects on membrane organization, intracellular signaling pathways, transcriptional regulation, and lipid mediator production. Although these mechanisms have been extensively characterized in humans and rodents, their investigation in dogs has progressed more gradually. Early studies focused primarily on the effects of dietary fish oil supplementation on inflammatory mediators and immune function, evaluating outcomes such as eicosanoid production, T-cell subsets and responses, antibody production, and neutrophil function. These pioneering studies established that dietary fatty acid composition could modulate canine immune responses and provided the first evidence supporting the immunomodulatory potential of LC n-3 PUFAs in dogs. Building on these observations, subsequent research has benefited from advances in the mechanistic understanding of PUFA biology, suggesting that their immunological effects may extend beyond changes in eicosanoid production to include modulation of membrane organization, intracellular signaling pathways, transcription factors, and SPMs. More recently, research has expanded from traditional fish oil supplementation to the evaluation of alternative and more sustainable PUFA sources while applying this mechanistic framework to assess their biological efficacy. The following sections review the available evidence regarding the effects of dietary PUFA supplementation on canine immune function, with particular emphasis on their potential as functional ingredients for modulating inflammation and supporting health in dogs. Effects of PUFAs on canine immune responses Effects in healthy dogs The impact of PUFAs on the immune responses in healthy dogs has been explored, and is described in Table 3. Diets with n-6:n-3 ratios ranging from 0.7:1 to 10:1, particularly those enriched with fish oil, were shown to alter leukotriene synthesis, favoring increases in LTB5 and/ or decreases in LTB4 in the skin, plasma, and neutrophils of adult and elderly dogs, compared to diets with higher n-6:n-3 ratios (25:1 to 100:1; Byrne et al., 2000; Hall et al., 2005; Vaughn et al., 1994). The presence of EPA and DHA in the diet influences fatty acid composition and function of neutrophil membranes, rather than the low n-6:n-3 ratio alone, as shown by Waldron et al. (2012). These authors reported higher LTB5 and lower LTB4 in neutrophils of dogs fed a diet enriched with EPA and DHA from menhaden fish oil (0.34:1; 3.07 g/100g food of EPA and 1.00 g/100g of DHA), compared to a diet containing linseed oil, with a similar ratio (0.38:1), but lacking LC n-3. Table 3Studies on effects of dietary inclusion of polyunsaturated fatty acids on immune parameters of healthy dogs.Table 3 dummy alt textAnimalsDietExperimental design/ Duration of the trialImmune parametersReference8 male and 8 female Beagle dogs/ 6-7 months oldn-3 diet containing deodorized menhaden oil (14% EPA, 8% DHA, 30% other n-3) and n-3 ethyl ester concentrate (44% EPA, 24% DHA, 10±12% other n-3), with a 0.7:1 n-6:n-3 ratio; n-6 diet containing corn oil, with a 45.0:1 n-6:n-3 ratio8 dogs per group/ six weeks/ Induction of LTB4 production in neutrophils with calcium ionophore A23187↓ Neutrophil LTB4 production in dogs fed with n-3 diet(Byrne et al., 2000)10 geriatric female Beagle dogs/ 7-10 years old/ 4 additional healthy Beagles1n-3 diet containing fish oil, with a 1.31:1 n-6:n-3 ratio; n-6 diet containing corn oil, with a 40.6:1 n-6:n-3 ratio5 dogs per experimental group/ 36 weeks↑ Neutrophil LTB5 and LTB5 to LTB4 ratio in dogs fed n-3 diet;No effects on neutrophil LTB4(Hall et al., 2005)15 male and 15 female Beagle dogs/ 1 year oldFive diets with different n-6:n-3 ratios: 5:1, 10:1, 25:1, 50:1 and 100:1; Ratios were obtained by combining fish oil, flax oil and safflower oil6 dogs per experimental group/ 12 weeks/ Induction of LTB production in skin with injection of 0.1mg of LPS, and in neutrophils with calcium ionophore A23187↓ LTB4 and ↑ LTB5 in skin, neutrophils and plasma of dogs fed 5:1 and 10:1;No effects on neutrophil respiratory burst activity(Vaughn et al., 1994)40 male and female dogs of different breeds/ 1.5-7 years oldFour diets containing menhaden fish oil (MHO, 0.34:1 n-6:n-3 ratio), linseed oil (LSO, 0.38:1 n-6:n-3 ratio), beef tallow (BTO, 9.7:1 n-6:n-3 ratio) or safflower oil (SFO, 100:1 n-6:n-3 ratio) at 18 g oil/100g diet; EPA and DHA not detected in LSO, BTO and SFO; MHO with 3.07% of EPA and 1.00% of DHA10 dogs per experimental group/ 28 days/ Induction of LTB4 production in neutrophils with calcium ionophore A23187; induction of superoxide production in neutrophils with PMA↑ Neutrophil LTB5 in dogs fed LSO and MHO, compared to SFO and BTO;↑ Neutrophil LTB5 in dogs fed MHO, compared to LSO;↓ Neutrophil LTB4 in dogs fed MHO, when compared to SFO, BTO and LSO↓ Neutrophil superoxide production in dogs fed LSO and MHO(Waldron et al., 2012)20 female geriatric Beagle dogs/ 9.5-11.5 years oldThree diets with different n-6:n-3 ratios: 1.4:1 (high n-3), 5.4:1 (medium n-3) and 31:1 (low n-3); n-3 sourced from fish oil and n-6 sourced from corn oil6 dogs in the low n-3 diet, 7 dogs in both medium and high n-3 diets/ 12 weeks/ DTH response tested at 10.5 weeks; at 60 and 74 days, dogs were vaccinated with KLH suspension↓ DTH skin test and PGE2 concentration in mononuclear cells stimulated with LPS, ↓ Plasma α-tocopherol and ↑ plasma TBARS in dogs fed high n-3;No effects on antibody titers against KLH(Wander et al., 1997)20 elderly female Beagle dogs/ 9.5-11.5 years oldThree diets with different n-6:n-3 ratios: 1.4:1 (high n-3), 5.4:1 (medium n-3) and 31:1 (low n-3); n-3 sourced from fish oil and n-6 sourced from corn oil6 dogs in the low n-3 diet, 7 dogs in both medium and high n-3 diets/ 11 weeks/ At 8 and 10 weeks, dogs were vaccinated with KLH suspension↑ Total lymphocyte numbers and ↓ CD4+ T-lymphocytes and CD4+/CD8+ ratio in dogs fed high n-3, after vaccination(Hall et al., 1999)32 healthy female geriatric Beagle dogs/ 7 to 10 years oldThree diets with a 1.4:1 n-6:n-3 ratio (high n-3, from fish oil) and three diets with a 40:1 n-6:n-3 ratio (low n-3, from corn oil), containing different concentrations of α-tocopheryl acetate: 17, 101 and 447 mg/kg; Control diet with a 40.1:1 n-6:n-3 ratio and 17 mg/kg α-tocopheryl acetate5 or 6 dogs per experimental group/ 17 weeks/ Blood samples collected before and after 12 weeks of feeding/ Inoculation with KLH suspension at 13 weeks and blood collected on days 1 and 4 post injection; second inoculation with KLH at week 15 and blood collected on days 1 and 4 post injection; DTH response tested 1 day after the second inoculation; serum antibody titers against KLH determined at 17 weeks↑ DTH in dogs fed the low n-3 and medium dose of α-tocopheryl, at 72 and 96 hours;↑ Lymphocyte counts in dogs fed high dose of α-tocopheryl, after both inoculations;↑ Lymphocyte counts in dogs fed high n-3, compared to dogs fed low n-3, after the first inoculation;↑ % of CD8+ T-cells and ↓ CD4+/CD8+ ratio in dogs fed medium and high doses of α-tocopheryl, compared to dogs fed the low dose, at weeks 12;↑ CD4+/CD8+ ratio in dogs fed high n-3 and low α-tocopheryl after the second inoculation;No effects on lymphocyte counts after 12 weeks of feeding, IL-2R and CD69 in cell surface, % of CD4+ T-cells, serum antibody titers against KLH and macrophage phagocytosis(Hall et al., 2003)25 adult male and 25 adult female Beagle dogs/ 1.4 to 14.2 years oldPretrial diet, without added fish oil, lysine, methionine, vitamins C and E; Control diet without fish oil, lysine and methionine, with ≥130 mg/kg of vitamin C and ≥640 IU/kg of vitamin E/ Four test diets with increasing concentrations of fish oil (0, 0.45, 0.9, 1.35%), added lysine and methionine, ≥130 mg/kg of vitamin C and ≥640 IU/kg of vitamin E10 dogs per experimental group/ All dogs were fed the pretrial diet, during 60 days; dogs were then fed with the test diets during 90 days/ Blood collected at the end of pretrial and 60 days after the beginning of feeding trial↑ Neutrophil bacterial killing, IL-8R and L-selectin mRNA levels and ↓ MPO, MyD88, TLR-2, TLR-4, NF-kB, TNF-α and COX-2 mRNA levels in dogs fed all the five test diets, from the end of pretrial to 60 days after feeding;No effects on ICE mRNA levels(Hall et al., 2011)8 intact females, 6 intact males and 1 castrated male Walker Hound-cross dogs/ 1 to 4 yearsFish oil diet: 0.6 g of sunflower oil and 7 g of menhaden fish oil (3.4:1 n-6:n-3 ratio; 1.75 g/kg diet of EPA and 2.2 g/kg of DHA); Fish oil + vitamin E diet: 0.6 g of sunflower oil, 7 g of menhaden fish oil and 0.17 g of α-tocopherol acetate; Control diet: 12.4 g of sunflower oil (24:1 n-6:n-3 ratio; <0.1 g/kg of EPA and 0.1 g/kg of DHA)5 dogs per experimental group/ 12 weeks↓ Lymphocyte proliferation in fish oil group;↓ PGE2 in fish oil and fish oil + vitamin E groups;No effects on the expression of IL-2R on activated lymphocytes;Decrease in lymphocyte proliferation was not significant in dogs receiving fish oil + vitamin E, compared to controls(LeBlanc et al., 2007)8 intact females, 6 intact males and 1 castrated male crossbred-hound dogs/ 1 to 4 years oldFish oil diet: 0.6 g of sunflower oil and 7 g of menhaden fish oil (3.4:1 n-6:n-3 ratio; 1.75 g/kg diet of EPA and 2.2 g/kg of DHA); Fish oil + vitamin E diet: 0.6 g of sunflower oil, 7 g of menhaden fish oil and 0.17 g of α-tocopherol acetate; Control diet: 12.4 g of sunflower oil (24:1 n-6:n-3 ratio; <0.1 g/kg of EPA and 0.1 g/kg of DHA)5 dogs per experimental group/ 12 weeks/ IV injection with LPS from E. coli serotype O55:B5 after 12 weeksNo effects on serum cytokines and PGE2 before LPS injection;↓ Serum IL-1 activity in fish oil and fish oil + vitamin E groups after LPS injection;↓ Serum IL-6 after LPS injection in fish oil group;No effect on TNF-α after LPS injection(LeBlanc et al., 2008)18 young and 18 adult Fox Terriers and Labrador Retrievers/ Mean ages 1.8 and 11.5 years old5:1 diet: 6.50% chicken fat, 1.65% fish oil and 0.24% ground flaxseed (5:1 n-6:n-3 ratio); 25:1: 8.21% of chicken fat (25:1 n-6:n-3 ratio)All dogs fed the 25:1 diet, for 8 weeks (Phase I)/ 18 dogs were switched to the 5:1 diet and fed their respective diets for the following 8 weeks (Phase II)/ Intramuscular injection with a suspension of sheep red blood cells at the end of Phase II↑ Mitogen response of PBMCs to ConcA, PHA and PWM in young dogs fed 5:1 diet;↑ PGE3 production by PBMCs in both young and old dogs fed the 5:1 diet;↓ Serum MDA, γ-tocopherol and antibody titers in aged dogs fed 5:1 diet, at 7 days post immunization;No effect on mitogen responses of old dogs, IL-1, IL-6, TNF-α and PGE2 production of PBMCs and peritoneal cells, PGE3 produced by peritoneal macrophages, serum α-tocopherol and 4-HNE(Kearns et al., 1999)22 male and 26 female Beagle puppies/ 8 weeks oldLow-DHA diet: < 0.01% DHA as-fed basis, 60.5 IU/kg dl-α-tocopherol and 0.08% taurine; Moderate-DHA diet: 0.095% DHA, 311.6 IU/kg dl-α-tocopherol and 0.15% taurine; High-DHA diet: 0.19% DHA, 816 IU/kg dl-α-tocopherol and 0.14% taurine16 puppies per group/ Puppies were fed the experimental diets between 8 and 52 weeks of age; Anti-rabies antibody titers were measured at 16 weeks (prior to vaccination) and at 17, 18, 20, and 24 weeks of age↑ Serum anti-rabies antibody titers at 17 and 18 weeks of age in puppies fed high DHA;No effects at 20 and 24 weeks of age(Zicker et al., 2012)6 adult male and 6 female Beagle dogs/ 1.5 years old0 or 0.4% of Schizochytrium sp. containing 20.48% of DHA (DM basis)Completely randomized design with 6 dogs per experimental group/ 31 daysSchizochytrium sp. increased numbers of phagocytic monocytes and granulocytes, phagocytosis of monocytes, and decreased phagocytosis of granulocytes;No effects on % of Th-suppressor lymphocytes(Souza et al., 2019)6 spayed female, 2 intact male and 4 neutered male Beagle dogs/ 5.4±0.57 years oldControl diet containing 5% of shrimp hydrolysate and 3% of salmon oil; Experimental diet containing 5% of fish hydrolysate, and 3.2% of fish oil derived from local produced fish by-productsCrossover design with 6 dogs per diet and period/ periods of 6 weeksNo effects on serum IL-1β, IL-8, and IL-12/IL-23 p40, adiponectin, CRP and fecal IgA concentrations;IL-10, TNF-α, and IFN-γ were below the detection limits(Cabrita et al., 2024b)17 adult Beagle dogs/ 3-5.5 years old (n=11); 9 years old (n = 6)Substitution of 1% of chicken fat (9.3:1 n-6:n-3 ratio; 0.03 g/kg food of EPA and 0.06 g/kg of DHA) by 1% of salmon oil, from two sources: fresh Norwegian salmon oil (NSO; 5.0:1 n-6:n-3 ratio; 0.48 g/kg of EPA and 0.64 g/kg of DHA) and Scotland salmon oil (SSO; 5.1:1 n-6:n-3 ratio; 0.59 g/kg of EPA and 0.89 g/kg of DHA)Randomized controlled trial composed of three periods of 14 days each: all dogs were fed with the chicken fat diet (period 1); 8 dogs received NSO diet and 9 dogs received SSO diet (period 2); then all dogs received the chicken fat diet (period 3)/ 42 daysNo effects on plasma IgA and IgG(Hesta et al., 2012)12 healthy adult male unneutered Beagle dogs/ Mean age 3.0 years old15 g of a control snack containing 0.01% EPA (DHA below the detection limit) or 15 g of an experimental snack enriched with 0.5% krill oil, providing 0.06% EPA and 0.05% DHA (DM basis).6 dogs per experimental group/ 8 weeks↑ Serum IgE, SOD, GSH-Px and CAT in dogs fed the experimental snack;↓ Serum TNF-α, IL-1β, IL-8 and MDA in dogs fed the experimental snack;No effects on serum IgM and IgA(Wang et al., 2025)12 male and 6 female Golden Retriever dogs/ 6±2.1 years oldControl diet: 6% of poultry fat; BSF3% diet: 3% of poultry fat and 3% of black soldier fly larvae (BSFL) fat; BSF6%: 6% of BSFL fat; BSFL fat contains 42.84% lauric acid, 17.02% palmitic acid, 14.60% oleic acid, 9.90% LA, and 0.12% ALA6 dogs per group/ 30 daysNo effects on MDA levels and serum IgE and IgG concentrations(Kahraman et al., 2025)5 female Beagles and 5 female Greyhounds/ 2-9 years oldSupplementation with Melrose®flaxseed oil containing 57% ALA and 17% LA, at the rate of100 mL/kg foodAll dogs were treated with flaxseed oil/ 3 weeks↓ IL-1β and HSP90 expression in white blood cells of Greyhounds at the end of the trial;No effects on IL-1β and HSP90 of Beagle dogs;No effects on HSP70(Purushothaman et al., 2014)13 male and 17 female client owned dogs of different breeds/ 7.2±3.1 years oldThree extruded diets containing camelina oil (1:1.18 n-3:n-6 ratio), flaxseed oil (1:4.19 n-3:n-6 ratio) or canola oil (1:0.59 n-3:n-6 ratio), at 8.2 g oil/100g of total food intakeRandomized complete block design with 10 dogs per experimental group/ 16 weeksNo effects on serum PGE2, JUP, GAG and NO(Richards et al., 2023)25 female Teddy dogs/ 1-2 years old0, 0.5, 1, 2 and 4% of hemp oil (58.71% LA and 16.81% ALA)5 dogs per experimental group/ 30 days↑ Serum IgM (1, 2 and 4%), IFN-γ (1 and 2%) and SOD (2 and 4%);↓ Serum MDA (2%);Metabolomics analysis: ↓ PGE₂, PGD2 and TXB₂ (1, 2%); ↑ LTB₄ (0.5%), ↑ 20-HETE (4%);No effect on serum complement C4, IgG, IgE(Xin et al., 2022)6 male and 10 female Beagle dogs/ 18 months old0 or 0.5% of conjugated linoleic acid (CLA; 60% methyl-ester linoleic conjugated acid in 1:1 ratio of 9-cis:11-trans; 10-trans:12-cis isomers)8 dogs per experimental group /9 months↑ Proliferation of blood lymphocytes of dogs fed CLA diet, after ConcA stimulation;No effects on lysosomal volume, phagocytic capacity and superoxide anion of polymorphonuclear blood cells(Nunes et al., 2008)1Age and sex of dogs not provided.ALA: α-linolenic acid; C4: Complement component 4; CAT: Catalase; CD: Cluster of differentiation; ConcA: Concanavalin A; COX-2: Cyclooxygenase-2; CRP: C-reactive protein; DHA: Docosahexaenoic acid; DM: Dry matter; DTH: Delayed-type hypersensitivity response; EPA: Eicosapentaenoic acid; E. coli: Escherichia coli; GAG: Glycosaminoglycan; GSH-Px: Glutathione peroxidase; ICE: Interleukin converting enzyme; IFN-γ: Interferon gamma; Ig: Immunoglobulin; IL: Interleukin; IL-2R: Interleukin 2 receptor; IL-8R: Interleukin 8 receptor; IV: Intravenous; JUP: Junction plakoglobin; HSP: Heat shock protein; KLH: Keyhole limpet hemocyanin; LA: Linoleic acid; LPS: Lipopolysaccharide; LTB: Leukotriene B; MDA: Malondialdehyde; MPO: Myeloperoxidase; MyD88: Myeloid differentiation primary response 88; n-3: Omega-3 PUFA; n-6: Omega-6 PUFA; NF-κB: Nuclear factor-κB; NO: Nitric oxide; PBMCs: Peripheral blood mononuclear cells; PGD2: Prostaglandin D2; PGE: Prostaglandin E; PHA: Phytohemagglutinin; PMA: Phorbol myristic acetate stimulated; PWM: Pokeweed mitogen; SOD: Superoxide dismutase; TBARS: thiobarbituric acid reactive substances; TLR: Toll-like receptor; TNF-α: Tumor necrosis factor alpha; 4-HNE: 4-hydroxynonenal; 20-HETE: 20-Hydroxyeicosatetraenoic acid. Upward arrows (↑) indicate a significant increase, while downward arrows (↓) indicate a significant decrease in the parameters analysed. Parameters for which no significant differences were observed are reported as such in the table. Studies on effects of dietary inclusion of polyunsaturated fatty acids on immune parameters of healthy dogs. Age and sex of dogs not provided. ALA: α-linolenic acid; C4: Complement component 4; CAT: Catalase; CD: Cluster of differentiation; ConcA: Concanavalin A; COX-2: Cyclooxygenase-2; CRP: C-reactive protein; DHA: Docosahexaenoic acid; DM: Dry matter; DTH: Delayed-type hypersensitivity response; EPA: Eicosapentaenoic acid; E. coli: Escherichia coli; GAG: Glycosaminoglycan; GSH-Px: Glutathione peroxidase; ICE: Interleukin converting enzyme; IFN-γ: Interferon gamma; Ig: Immunoglobulin; IL: Interleukin; IL-2R: Interleukin 2 receptor; IL-8R: Interleukin 8 receptor; IV: Intravenous; JUP: Junction plakoglobin; HSP: Heat shock protein; KLH: Keyhole limpet hemocyanin; LA: Linoleic acid; LPS: Lipopolysaccharide; LTB: Leukotriene B; MDA: Malondialdehyde; MPO: Myeloperoxidase; MyD88: Myeloid differentiation primary response 88; n-3: Omega-3 PUFA; n-6: Omega-6 PUFA; NF-κB: Nuclear factor-κB; NO: Nitric oxide; PBMCs: Peripheral blood mononuclear cells; PGD2: Prostaglandin D2; PGE: Prostaglandin E; PHA: Phytohemagglutinin; PMA: Phorbol myristic acetate stimulated; PWM: Pokeweed mitogen; SOD: Superoxide dismutase; TBARS: thiobarbituric acid reactive substances; TLR: Toll-like receptor; TNF-α: Tumor necrosis factor alpha; 4-HNE: 4-hydroxynonenal; 20-HETE: 20-Hydroxyeicosatetraenoic acid. Upward arrows (↑) indicate a significant increase, while downward arrows (↓) indicate a significant decrease in the parameters analysed. Parameters for which no significant differences were observed are reported as such in the table. Excessive n-3 supplementation levels may impair immune function and increase lipid peroxidation. Wander et al. (1997) showed that elderly Beagles fed a diet high in n-3 (1.4:1 n-6:n-3 ratio) for 12 weeks had suppressed T-cell responsiveness, evidenced by the decreased DTHresponse, lower production of PGE2 by PBMCs stimulated with LPS, decreased plasma α-tocopherol levels, and increased TBARS. The authors suggested that the lower DTH response was independent of PGE2, which can suppress T-cell proliferation through inhibition of IL-2 production (Sreeramkumar et al., 2012), and might be related to the impaired vitamin E status and increased lipid peroxidation (Wander et al., 1997). Hall et al. (1999) found a decrease in the percentage of CD4+ T-cells and in the CD4+/CD8+ T-cell ratio in dogs fed high n-3 (1.4:1 n-6:n-3 ratio), despite the increases in total lymphocyte counts after inoculation with keyhole limpet hemocyanin, suggesting an effect on the CD4+ T-cell subset. Hall et al. (2003) tested the diet with a 1.4:1 n-6:n-3 ratio and various α-tocopheryl acetate concentrations (17, 101, and 447 mg/kg of food) in elderly female Beagles for 17 weeks. The results suggested a more pronounced effect of vitamin E, rather than fatty acid content. A high n-3 level suppressed the DTH skin test, while a low n-3 and an optimal α-tocopheryl level (101 mg/kg of food) produced the largest DTH response. Furthermore, medium α-tocopheryl levels led to increased CD8+ T-cell numbers and a decreased CD4+/CD8+ ratio. The authors suggest that vitamin E enhanced the DTH response by increasing CD8+ T-cell numbers and that dietary n-3 diminished the effects of vitamin E. Similarly, the results of Hall et al. (2011) suggested a role of vitamin E in immune function, with no impact from fatty acid or amino acid supplementation (Table 3). Adult dogs given diets containing fish oil (3.4:1 n-6:n-3 ratio) for 12 weeks showed decreased lymphocyte proliferation and PGE2 production in PBMCs. Vitamin E supplementation (0.17 g) attenuated the effects of fish oil in cell proliferation, as the reduction observed was less prominent than in dogs fed the fish oil diet (LeBlanc et al., 2007). The authors concluded that n-3 content in the diet decreased lymphocyte proliferation by a mechanism independent of PGE2 and not associated with lipid peroxidation, and failed to correlate this effect with the expression of IL-2 receptor in cells. LeBlanc et al. (2008) analyzed similar diets in dogs stimulated with LPS, showing decreases in serum levels of PGE2 and IL-1 and IL-6 activities, without any effect on TNF-α, suggesting therapeutic potential of fish oil-rich diets for dogs with chronic inflammatory diseases. Kearns et al. (1999) fed young and aged Fox Terriers and Labrador Retrievers diets with fish oil and ground flax seed (5:1 n-6:n-3 ratio) or chicken fat (25:1 n-6:n-3 ratio) and suggested that a diet with a 5:1 ratio exerts a positive effect on immune responses of both young and aged dogs and highlighted the need for specific dietary fatty acid profiles for dogs of different breeds and life stages. The effects of n-3 on the immune response of puppies are poorly understood. Zicker et al. (2012) addressed the supplementation of DHA from fish oil in cognitive learning, memory, psychomotor, visual health, and immunological function of healthy puppies from 8 to 52 weeks of age. Dogs fed the DHA enriched diet showed significantly higher anti-rabies antibody titers, at 1 and 2 weeks after vaccination. However, this diet also had the highest concentrations of vitamin E and taurine, and the results may be related to the complexity of the diet rather than DHA alone. While fish oil has traditionally been the most common source of dietary LC n-3 PUFAs evaluated in canine studies, growing sustainability concerns have led to the introduction of alternative sources rich in EPA and DHA. Still, research investigating the immunological effects of these novel sources in dogs remains limited. Souza et al. (2019) investigated the supplementation with 0.4% of Schizochytrium sp. as a source of DHA (20.48% DM) in adult Beagle dogs during 31 days and showed increased circulating numbers of phagocytic monocytes and granulocytes and phagocytic activity of monocytes. Conversely, a decrease in phagocytic activity of granulocytes was observed, and no effects were reported on FoxP3+ T-cells. As DHA is a precursor of SPMs, supplementation with Schizochytrium sp. might lead to decreased accumulation of neutrophils in inflammation sites, promoting resolution via monocyte and macrophage uptake of debris and removal of apoptotic neutrophils (Serhan & Petasis, 2011). Cabrita et al. (2024b) investigated the effects of a diet containing protein hydrolysate and oil derived from fish waste (1.25 g/100g of total fatty acids of EPA and 1.96 g/100g of total fatty acids of DHA) in Beagle dogs. Although serum inflammatory markers (IL-1β, IL-8, and IL-12/IL-23 p40), CRP, anti-inflammatory adiponectin, and fecal immunoglobulin (Ig) A concentrations showed no significant changes, the diet potentially benefited bacterial genera associated with a healthy microbiome. In another study, Hesta et al. (2012) tested the substitution of 1% of chicken fat (9.3:1 n-6:n-3 ratio) by 1% of salmon oil from different sources and no significant differences were observed in plasma IgA and IgG levels, which may be related to the low administration level or duration of supplementation (14 days). Wang et al. (2025) evaluated the effects of supplementing Beagle dogs with 0.5% of krill oil (0.06% EPA and 0.05% DHA on a DM basis) provided in snacks for 8 weeks. The authors observed increased serum IgM, superoxide dismutase (SOD), catalase, and glutathione peroxidase levels, while TNF-α, IL-1β, IL-8 and MDA levels decreased, showing the potential immunomodulatory, anti-inflammatory and antioxidant properties of krill oil. Only a few studies have investigated the potential effects of ALA and LA on canine immunity. To date, the effects of insect supplementation in diets for dogs remain poorly explored. One study tested the substitution of poultry fat by 3% or 6% of BSFL fat, rich in lauric acid (42.84%) and containing lower amounts of LA and ALA (9.90% and 0.12%, respectively), during 30 days. The authors observed no adverse health effects of insect supplementation and no significant changes in serum IgE and IgG levels (Kahraman et al., 2025). Insect-derived fats may represent a promising sustainable source of dietary fatty acids for canine nutrition, although additional studies are required to better characterize their nutritional and immunological effects. Most of the available evidence regarding the effects of LA and ALA on canine immunity has been obtained from studies using plant oils. Purushothaman et al. (2014) tested the supplementation of 100 mL/kg food of Melrose® flaxseed oil (57% ALA and 17% LA) in Beagle and Greyhound dogs, during 3 weeks. Breed-specific responses to flaxseed oil were observed, with Greyhounds exhibiting reduced IL1β and heat shock protein 90 expression in their white blood cells, whereas Beagles showed no changes in inflammatory gene expression. Therefore, it would be beneficial to consider breed-specific differences when evaluating dietary interventions. Richards et al. (2023) tested camelina oil (1:1.18 n-3:n-6 ratio) top-dressed in a commercial diet, in comparison with flaxseed (1:4.19 n-3:n-6 ratio) and canola (1:0.59 n-3:n-6 ratio) oils, in client-owned dogs over 16 weeks. Camelina oil supplementation was comparable to flaxseed and canola in terms of skin, coat health, and inflammatory and oxidative markers in healthy dogs, supporting the potential of this ingredient as an alternative source of PUFA in canine nutrition. In another study, Xin et al. (2022) supplemented diets for teddy dogs with 0, 0.5, 1, 2, or 4% of hemp oil (58.71% LA and 16.81% ALA) for 30 days and found increased serum IgM and IFN-γ in dogs fed 1 to 4%. Furthermore, 2% of hemp oil promoted antioxidant effects by increasing SOD and decreasing MDA levels. The authors also conducted a metabolomic analysis in dogs' serum, showing that moderate supplementation levels (1-2%) downregulated the metabolites PGE₂, prostaglandin D2 and TXB₂, whereas lower levels increased LTB₄, and excessive supplementation increased the cytochrome P450 metabolite 20-hydroxyeicosatetraenoic acid. These findings provide evidence that this source of PUFA may influence inflammatory lipid mediator profiles, depending on the supplementation levels. Based on these findings, the authors recommended supplementing teddy dogs with 1 to 2% of hemp oil to maximize the effects on immune and antioxidant functions. To the authors' knowledge, only one study has focused on the effects of conjugated linoleic acid (CLA), found in ruminant meat and milk, on the immune function of dogs (Nunes et al., 2008). The authors observed that supplementing diets with 0.5% of CLA for 9 months increased the proliferation of lymphocytes stimulated with concanavalin A but did not change lysosomal volume, phagocytic capacity, and superoxide anion of polymorphonuclear cells. Although the authors did not analyze the production of IL-2 in dogs fed the CLA diet, they suggested that the effects on lymphocyte proliferation might be related to an increased production of this cytokine. Effects in dogs with natural or experimentally induced pathologies A growing body of evidence supports the therapeutic potential of PUFAs in several canine inflammatory pathologies. Vendramini et al. (2025) recently reviewed the available literature on the efficacy and optimal dosages of n-3 in companion animals across different clinical areas, including cardiology, dermatology, and oncology. The authors highlighted the significant clinical benefits of n-3 supplementation in dogs, including antiarrhythmic effects, improvement of skin and clinical scores, and reduction of the use of immunosuppressive or nonsteroidal anti-inflammatory drugs. For dogs with cardiovascular diseases, the authors recommend doses ranging from 27 to 54.2 mg/kg of EPA and 18 to 40.6 mg/kg of DHA, whereas for canines with atopic dermatitis, they suggest levels that range from 39 to 43 mg/kg of EPA and 25 to 30 mg/kg of DHA. Due to the lack of studies in dogs with cancer, the authors did not recommend specific dosages but acknowledged the potential of n-3 based on results conducted in humans. Table 4 summarizes published studies on the effects of dietary inclusion of PUFAs on immune parameters of dogs with natural or induced pathologies. Heart failure is deeply associated with systemic inflammation and cachexia, the latter characterized by the loss of lean body mass. This condition is associated with high levels of inflammatory mediators, including IL-1β, IL-6 and TNF-α, and reduced survival (Freeman, 2010; Freeman, 2012). Dogs with heart failure supplemented with 27 mg/kg of EPA and 18 mg/kg of DHA daily showed decreased IL-1 production and improved cachexia, with the reduction in the levels of this cytokine being correlated with survival, thus suggesting that targeting inflammatory cytokines could benefit dogs with heart failure (Freeman et al., 1998). On the contrary, Nasciutti et al. (2021) showed no significant effects on IL-1β, IL-6, TNF-α and CRP of client-owned dogs in stages B2 and C of myxomatous mitral valve disease after being supplemented with 170 mg EPA+DHA/100kcal during 12 months. However, n-3 supplementation reduced the volumetric overload and showed antiarrhythmic effects, keeping dogs in milder stages of the disease. Table 4Studies on effects of dietary inclusion of polyunsaturated fatty acids on immune parameters of dogs with natural or experimentally induced pathologies.Table 4 dummy alt textAnimalsDietExperimental design/ Duration of the trialImmune parametersReference28 dogs with stable chronic heart failure/ 8.0±2.8 years old; 5 healthy dogs for baseline comparison/ 7.4±3.2 years oldSupplementation of fish oil ethyl esters in capsules containing 27 mg/kg of EPA and 18 mg/kg of DHA per day; Placebo containing corn oil ethyl esters in identical capsulesClinical trial with 14 dogs per experimental group/ 8 weeks↓ Production of IL-1 in dogs treated with fish oil;Tendency for a lower production of PGE2 of PBMCs stimulated with 100 ng/mL of E. coli endotoxin (P=0.07) of dogs fed with fish oil;No effects on TNF production by PBMCs(Freeman et al., 1998)29 owned dogs with myxomatous mitral valve disease stages B2 and C/ 11.56±2.76 years old (n-3 group) and 11.67±2.02 years old (control)Supplementation with 0 (control) or 170mg EPA+DHA/100kcal (n-3)Double-blinded randomized trial with 16 dogs in the n-3 group and 13 dogs in the control group/ 12 monthsNo effects on IL-1β, IL-6, TNF-α and CRP(Nasciutti et al., 2021)20 adult Mongrel dogs with induced atrial fibrillation1Supplementation with 0 (control) or 0.6 g/kg per day of EPA+DHA (FO)11 dogs in the control group and 9 dogs in the FO group/ 3 weeks before surgery; excision of the left atrial appendagePeak neutrophil to lymphocyte ratio was lower and decayed faster in FO group;↓ Inflammatory cell infiltration in atria and post-surgical atrial expression of iNOS in FO group;No effects on CRP(Mayyas et al., 2011)24 male Beagle dogs/ 12 dogs with induced atrial fibrillation (AF) and 12 dogs sham-operated1Supplementation with 0 (sham-operated and AF groups) or 0.6 g/kg per day of EPA+DHA (FO and AF+FO groups)6 dogs per experimental group/ Feeding trial initiated 1 week before surgery (long-term rapid atrial pacing) and continued for 4 weeks post operation/ Gene expression analyzed in the left atrium↑ Expression of IL-1β, IL-6 and TNF-α in AF group;↓ Expression of IL-1β, IL-6 and TNF-α in the AF+FO compared to AF;↓ Expression of IL-1β, IL-6 and TNF-α in the FO compared to sham-operated(Tu et al., 2022)20 adult Mongrel dogs with induced sterile pericarditis1Oral administration of 0 (control) or 2 g/day of EPA+DHA10 dogs per experimental group/ 4 weeks before the operation until the 2nd post-operative dayNo effects on serum CRP, IL-6 and TNF-α, before operation;Increased CRP, IL-6 and TNF-α, after operation in both groups;↓ Plasma CRP, IL-6 and TNF-α after operation in supplemented group(Zhang et al., 2011)25 adult Mongrel dogs with induced experimental myocardial infarction1Supplementation with 0 (control) or 100 mg/kg per day of EPA-ester (EPA)15 dogs in the control group and 10 dogs in the EPA group/ 8 weeks/ Experimental myocardial infarction induced after 8 weeks↓ Chemotactic response of neutrophils to LTB4 both before and after experimental myocardial infarction, ↓ myeloperoxidase activity and ↓ 12-HETE concentrations in the infarcted myocardium in dogs treated with EPA(Otsuji et al., 1993)37 male and 35 female client-owned dogs with pruritus/ 5.8±2.6 (A), 5.2±2.4 (B), 6.3±3.6 (C) and 4.5±2.5 (D) years oldFour diets containing different n-6:n-3 ratios and doses of EPA and DHA: Diet A - 1:1, 4.47% (of total fat) of EPA and 4.67% of DHA; Diet B - 3:1, 4.49% of EPA and 4.70% of DHA; Diet C - 6:1, 1.14% of EPA and 1.17% of DHA; Diet D - 27:1, 0.00% of EPA and 0.00% of DHAClinical trial with 16 dogs on diet A, 17 dogs on diet B, 22 on diet C and 17 on diet D/ 8 weeks↓ Serum PGE2 concentration in dogs fed diet A;Tendency for a larger decrease in CRP concentrations in dogs fed diet C (P=0.09)(Nesbitt et al., 2003)30 client owned dogs with atopic dermatitis1Flaxseed oil capsules containing 114 mg of ALA/kg and 34 mg of LA/kg; Commercial product containing 50 mg/kg of EPA and 33 mg/kg of DHA; Placebo containing 200 mg/kg of a mineral oilDouble blind, placebo-controlled, randomized clinical trial with 10 dogs per experimental group/ 10 weeksNo effect on LTB4 and PGE2 in skin samples(Mueller et al., 2005)30 male and female Beagle dogs1Five diets containing menhaden, flax and safflower oils, at different n-6:n-3 ratios: Diet A - 5.31:1; Diet B - 10.4:1; Diet C - 24.1:1; Diet D - 51.6:1; Diet E - 95.8:16 dogs per experimental group/ 12 weeks/ Biopsy specimens collected from 4-day wounds of each dog and analyzed by gas chromatography-mass spectrometry↓ Relative ratio of 13, 14-dihydro-15-keto PGA2 to 13, 14-dihydro-15-keto PGA3 in wound tissues of dogs fed diet A, compared to diet E(Mooney et al., 1998)12 female Beagle dogs1Control diet: Canned-food containing soya oil with a n-6:n-3 ratio of 7.7:1; Experimental diet: the same diet containing menhaden fish oil with a n-6:n-3 ratio of 0.3:16 dogs per experimental group/ 30 days/ Open and sutured cutaneous wounds were created on the trunk of the dog; eicosanoids were evaluated in open and sutured wounds after 5 daysTendency for lower PGE2 in open wounds of dogs fed the experimental diet (P=0.076), while no effects were observed for LTB4, 11-DTxB2 and TxB2, compared to controls;No effects on PGE2, LTB4, 11-DTxB2 and TxB2 in closed wounds(Scardino et al., 1999)12 client-owned dogs, with histologically confirmed spontaneously occurring nasal tumors/ > 2 years oldControl diet containing soybean oil (7.7:1 n-6:n-3 ratio, 0.1 g/kg DM of EPA and 0.2 g/kg of DHA); Experimental diet containing menhaden oil (0.3:1 n-6:n-3 ratio, 29 g/kg DM of EPA and 24 g/kg of DHA)Randomized, double-blind, placebo-controlled clinical trial with 6 dogs per group/ Trial began 1 week before and finished 6 weeks after the 4-week course of megavoltage radiation therapy↓ PGE2 and 11-DTxB2 concentrations in skin biopsies exposed to high radiation doses, in dogs fed menhaden fish oil;Tendency for decreased MMP-9 with increasing plasma EPA and DHA levels;No effects on LTB4 and TXB2(Hansen et al., 2011)1Age of dogs was not provided in the study.CRP: C-reactive protein; DHA: Docosahexaenoic acid; DM: Dry matter; E. coli: Escherichia coli; EPA: Eicosapentaenoic acid; IL: Interleukin; iNOS: inducible nitric oxide synthase; LTB: Leukotriene B; MMP-9: Matrix metalloproteinase-9; n-3: Omega-3 PUFA; n-6: Omega-6 PUFA, PBMCs: Peripheral blood mononuclear cells; PGE: Prostaglandin E; TxB2: Thromboxane B2; 11-DTxB2: 11-dehydro-thromboxane; 12-HETE: 12-Hydroxyeicosatetraenoic acid Upward arrows (↑) indicate a significant increase, while downward arrows (↓) indicate a significant decrease in the parameters analysed. Parameters for which no significant differences were observed are reported as such in the table. Studies on effects of dietary inclusion of polyunsaturated fatty acids on immune parameters of dogs with natural or experimentally induced pathologies. Age of dogs was not provided in the study. CRP: C-reactive protein; DHA: Docosahexaenoic acid; DM: Dry matter; E. coli: Escherichia coli; EPA: Eicosapentaenoic acid; IL: Interleukin; iNOS: inducible nitric oxide synthase; LTB: Leukotriene B; MMP-9: Matrix metalloproteinase-9; n-3: Omega-3 PUFA; n-6: Omega-6 PUFA, PBMCs: Peripheral blood mononuclear cells; PGE: Prostaglandin E; TxB2: Thromboxane B2; 11-DTxB2: 11-dehydro-thromboxane; 12-HETE: 12-Hydroxyeicosatetraenoic acid Upward arrows (↑) indicate a significant increase, while downward arrows (↓) indicate a significant decrease in the parameters analysed. Parameters for which no significant differences were observed are reported as such in the table. A limited number of studies focused on the anti-inflammatory effects of n-3 using induced models of atrial fibrillation, a condition that is associated with infiltration of immune cells in cardiac tissues and increased levels of inflammatory mediators (Hu et al., 2015). Mayyas et al. (2011) supplemented mongrel dogs with 0.6 g/kg/day of EPA and DHA 3 weeks prior to the excision of the left atrial appendage. The authors showed decreased inflammatory cell infiltration and expression of inducible nitric oxide synthase in atria, and the peak neutrophil-to-lymphocyte ratio was lower and decayed faster relative to the control group. A similar level of EPA and DHA fed to Beagle dogs with induced atrial fibrillation during 4 weeks decreased the expression of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α (Tu et al., 2022). Likewise, Zhang et al. (2011) demonstrated that mongrel dogs supplemented with 2 g/day of EPA+DHA during 4 weeks, followed by induced sterile pericarditis, showed decreased circulating CRP, IL-6 and TNF-α levels. The mechanisms by which PUFAs regulated pro-inflammatory cytokines were not addressed in this study, but the authors suggest that this downregulation might be related to the activation of PPAR signaling and subsequent inhibition of the NF-κB pathway. Dietary PUFA supplementation was able to attenuate the inducibility, vulnerability, and maintenance of AF in this model of pericarditis, with the reduction in the expression of pro-inflammatory cytokines likely contributing to the antiarrhythmic effects (Zhang et al., 2011). In a study using an induced model of infarcted myocardium, mongrel dogs supplemented with 100 mg/kg/day of EPA-ester during 8 weeks showed a reduced chemotactic response of neutrophils to LTB4. Furthermore, the authors observed lower myeloperoxidase activity, a marker of neutrophil infiltration, and lower concentrations of 12-hydroxyeicosatetraenoic acid, an ARA-derived eicosanoid, in the infarcted tissue (Otsuji et al., 1993). These results showed that dietary EPA attenuates ischemic myocardial damage through inhibition of neutrophilic infiltration into the infarcted myocardium. Proposed mechanisms of action of n-3 in dogs with dermatological conditions include eicosanoid production or inhibition of cellular activation (Mueller et al., 2004). However, published data show mild effects on eicosanoids, reinforcing the need for further research into the immunomodulatory pathways of n-3 in skin diseases. Nesbitt et al. (2003) tested four diets with different n-6:n-3 ratios and levels of EPA and DHA, offered to client-owned dogs with pruritus during 8 weeks, and found lower serum PGE2 concentrations in dogs fed the diet enriched with EPA and DHA (1:1; 4.47% of total fat of EPA and 4.67% of DHA). On the contrary, Mueller et al. (2005) found no significant changes in LTB4 and PGE2 concentrations in the skin of client-owned dogs with atopic dermatitis supplemented with a commercial product providing 50 mg/kg of EPA and 33 mg/kg of DHA during 10 weeks, suggesting that LTB4 and PGE2 may not play a significant role in the pathogenesis of canine atopic dermatitis or in the associated cutaneous inflammation and pruritus. The effects of n-3 during wound healing are poorly understood and are focused on eicosanoid production. Mooney et al. (1998) observed significant decreases in the relative ratio between 13,14-dihydro-15-keto PGA2 (a metabolite of PGE2) and 13,14-dihydro-15-keto PGA3 (a metabolite of PGE3) in dogs fed a 5.31:1 n-6:n-3 ratio diet for 12 weeks, compared with the 95.8:1 n-6:n-3 ratio diet. These molecules represent end points in the PGE pathway, indicating an active inflammatory process. These findings suggest that n-3 enriched diets may control inflammation associated with various dermatological conditions in dogs. However, Scardino et al. (1999) observed minor effects on eicosanoid levels, with a tendency for lower PGE2 in open wounds of Beagle dogs supplemented with a canned diet containing menhaden fish oil (0.3:1 n-6:n-3 ratio) compared to the same diet supplemented with soya oil (7.7:1 n-6:n-3 ratio) over 30 days, reinforcing the need for further research on the benefits of n-3 during inflammatory stages of wound healing. One study with client-owned dogs with naturally occurring nasal tumors and exposed to high radiation doses showed no effects of a diet containing menhaden oil (0.3:1 n-6:n-3 ratio, 29 g/kg EPA and 24 g/kg DHA) on LTB4 and TXB2 (Hansen et al., 2011), a stable metabolic product of TXA2 (Szczuko et al., 2021). However, skin biopsies of these dogs exhibited reduced levels of PGE2 and 11-dehydro thromboxane B2 (11-DTxB2), a metabolite of TXB2 (Szczuko et al., 2021), at 3 and 6 weeks after the beginning of the radiation therapy. The authors suggested that menhaden oil is most effective on eicosanoids produced via the inducible COX-2 enzyme and affects these inflammatory mediators late in tissue repair processes. Yet, the study shows some limitations, including the sample size and age of dogs, as inflammation can increase with age (Hansen et al., 2011). Clinical implications Current evidence supports the use of dietary PUFAs, particularly EPA and DHA, as part of the nutritional management of dogs with inflammatory conditions. Overall, the available studies suggest that n-3 PUFAs can modulate inflammatory and immune responses through multiple mechanisms, potentially contributing to improved clinical outcomes in disorders such as osteoarthritis, dermatological diseases, and cardiovascular conditions. However, the magnitude of these effects is influenced by several factors, including the PUFA source, dose, duration of supplementation, dietary n-6:n-3 ratio, and the individual characteristics of each animal. Therefore, based on the evidence currently available, no single dietary strategy can be recommended for all dogs. Instead, PUFA supplementation should be tailored to the individual clinical condition and integrated into an evidence-based nutritional plan. The quality and stability of PUFA-containing products should also be considered, as lipid oxidation during processing and storage may reduce their biological activity and, consequently, their nutritional value. The increasing availability of alternative PUFA sources, including microalgae, insects, krill, and fish by-products, represents an important opportunity to improve the sustainability of canine nutrition. Nevertheless, further studies are required to determine whether these novel sources provide immunological benefits comparable to those reported for traditional fish oil. Until more robust evidence becomes available, PUFA supplementation should be considered a valuable adjunct to established nutritional and therapeutic strategies rather than a standalone intervention. Concluding remarks and future perspectives This review brings together the current evidence on the effects of dietary PUFA supplementation on canine immune function, integrating findings from mechanistic studies with data obtained in healthy dogs and in dogs with naturally occurring or experimentally induced diseases. Overall, the available evidence indicates that PUFAs, particularly EPA and DHA, may influence immune function through multiple complementary mechanisms, including changes in membrane composition, regulation of intracellular signaling pathways, modulation of gene expression, and the production of bioactive lipid mediators involved in both the initiation and resolution of inflammation. These mechanisms are generally associated with reduced inflammatory responses and may contribute to improved clinical outcomes in several inflammatory conditions. Despite these promising findings, important knowledge gaps remain. Considerable heterogeneity among studies, particularly regarding PUFA sources, supplementation protocols, dietary n-6:n-3 ratios, treatment duration, and immune outcomes evaluated, makes direct comparisons difficult and limits the establishment of evidence-based nutritional recommendations. As a result, optimal supplementation strategies for different physiological and pathological conditions have yet to be defined. Future research should focus on well-designed clinical trials using standardized supplementation protocols and validated immune biomarkers. Particular attention should be given to establishing safe upper intake levels, evaluating the long-term effects of supplementation in different clinical settings, and defining optimal dietary n-6:n-3 ratios, despite evidence that ratios of 5:1 to 10:1 may exert beneficial immunomodulatory effects without compromising immune function. Advances in lipidomics, metabolomics, transcriptomics, and other omics technologies are also expected to improve our understanding of canine immunometabolism and may support the development of more personalized nutritional strategies that consider genetic background, gut microbiota composition, and disease status. At the same time, the identification of sustainable PUFA sources and the development of technologies that improve lipid stability and bioavailability, including natural antioxidants and nanotechnology-based delivery systems, are likely to shape the next generation of functional pet foods. Together, these advances will strengthen the scientific basis for PUFAs use in canine nutrition and support the development of more effective, sustainable, and evidence-based dietary strategies to support canine health. Ethical statement This article is a review and does not involve any original studies on animals or human participants conducted by the authors. Therefore, ethical approval and informed consent were not required. Funding C.B. thanks Associated Laboratory for Green Chemistry (LAQV), Network of Chemistry and Technology (REQUIMTE), for her Postdoctoral Fellowship (REQUIMTE 2024-03), supported by the Portuguese Foundation for Science and Technology (FCT/MCTES; UIDB/50006/2020, DOI 10.54499/UIDB/50006/2020; LA/P/0008/2020, DOI 10.54499/LA/P/0008/2020) through national funds. CRediT authorship contribution statement Carolina Barroso: Writing – review & editing, Writing – original draft, Conceptualization. António J.M. Fonseca: Writing – review & editing, Supervision, Conceptualization. Ana R.J. Cabrita: Writing – review & editing, Writing – original draft, Supervision, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Contributor Information António J.M. Fonseca, Email: ajfonseca@icbas.up.pt. Ana R.J. Cabrita, Email: arcabrita@icbas.up.pt. References